Henry Schein Q3 EPS Forecast Decreased by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research reduced their Q3 2026 earnings estimates for Henry Schein in a research note issued on Monday, May 25th. Zacks Research analyst Team now forecasts that the company will earn $1.38 per share for the quarter, down from their previous estimate of $1.43. The consensus estimate for Henry Schein’s current full-year earnings is $5.32 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2026 earnings at $1.42 EPS, Q1 2027 earnings at $1.37 EPS, Q2 2027 earnings at $1.40 EPS, Q3 2027 earnings at $1.46 EPS and Q4 2027 earnings at $1.58 EPS.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the prior year, the business posted $1.15 earnings per share. Henry Schein’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

Several other equities research analysts have also recently weighed in on HSIC. BTIG Research started coverage on shares of Henry Schein in a research report on Thursday, April 16th. They set a “neutral” rating for the company. Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Finally, Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and an average price target of $86.83.

Henry Schein Trading Up 2.4%

HSIC opened at $75.67 on Thursday. Henry Schein has a twelve month low of $61.94 and a twelve month high of $89.29. The company has a 50-day simple moving average of $74.32 and a 200 day simple moving average of $75.77. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.62 billion, a price-to-earnings ratio of 22.86, a P/E/G ratio of 1.85 and a beta of 0.82.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HSIC. Ameriprise Financial Inc. increased its stake in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares during the period. Bank of Montreal Can increased its stake in shares of Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares during the period. Norges Bank acquired a new position in shares of Henry Schein in the fourth quarter valued at approximately $88,116,000. Southpoint Capital Advisors LP increased its stake in shares of Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after buying an additional 700,000 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other news, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the transaction, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William K. Daniel bought 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 67,565 shares of company stock valued at $5,468,572. 0.89% of the stock is owned by company insiders.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.